vimarsana.com
Home
Live Updates
Pharming N : Group announces the launch of an offering of approximately €100 million convertible bonds due 2029 and the concurrent repurchase of the outstanding €125 million convertible bonds due 2025 - Form 6-K : vimarsana.com
Pharming N : Group announces the launch of an offering of approximately €100 million convertible bonds due 2029 and the concurrent repurchase of the outstanding €125 million convertible bonds due 2025 - Form 6-K : vimarsana.com
Pharming N : Group announces the launch of an offering of approximately €100 million convertible bonds due 2029 and the concurrent repurchase of the outstanding €125 million convertible bonds due 2025 - Form 6-K
Document
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
...
Related Keywords
Frankfurt ,
Brandenburg ,
Germany ,
Netherlands ,
Canada ,
Washington ,
United States ,
South Africa ,
France ,
Australia ,
London ,
City Of ,
United Kingdom ,
Italy ,
Amsterdam ,
Noord Holland ,
Japan ,
American Samoa ,
Italian ,
America ,
Michael Levitan ,
Van Lanschot Kempen ,
Lifespring Life Sciences Communication ,
Company The ,
Bonds ,
Commission File Number ,
Nasdaq ,
Exchange Commission ,
Pharming Group ,
Linkedin ,
Company Euronext Amsterdam ,
Vp Investor Relations Corporate Communications ,
Frankfurt Stock Exchange ,
Pharming Groupnv ,
Securities Exchange ,
File Number ,
Exact Name ,
Its Charter ,
Regulationst Rule ,
Securities Exchange Act ,
Sijmen De Vries ,
Euronext Amsterdam ,
New Bonds ,
Maturity Date ,
Shareholder Resolution ,
Cash Alternative Election ,
Long Stop Date ,
Fair Bond Value ,
Physical Settlement Notice ,
Physical Settlement Date ,
Open Market ,
Issue Date ,
Joint Global Coordinators ,
Joint Bookrunners ,
Lanschot Kempen ,
Eligible Bondholders ,
Invitation Settlement Date ,
Expiration Deadline ,
Securities Act ,
Joint Dealer Managers ,
North America ,
Middle East ,
Annual Report ,
Spring Life Sciences Communication ,
Chief Executive Officer ,